新型细胞学检测用于诊断复发性局灶节段性肾小球硬化
研究开发了一种非侵入性细胞学检测方法,用于诊断肾移植后复发性局灶节段性肾小球硬化(rFSGS)。该方法利用rFSGS患者血浆处理培养的足细胞,发现三个促凋亡基因(IL1β、BMF、IGFBP3)启动子驱动的荧光素酶报告活性升高,且对rFSGS与非复发FSGS或膜性肾病的鉴别AUC为0.81-0.86,IL1β和BMF细胞系敏感性和特异性均大于80%。
要点
- 基于足细胞报告基因的检测可非侵入性诊断肾移植后rFSGS。
- rFSGS患者血浆可激活IL1β、BMF和IGFBP3启动子驱动的报告基因。
- 该检测对rFSGS与非复发FSGS或膜性肾病的鉴别AUC为0.81-0.86。
核心结论
- 新型细胞学检测可准确、经济地诊断肾移植后复发性FSGS,并具有商业化推广潜力。
研究设计与样本
- 研究利用rFSGS患者血浆处理培养的足细胞,通过mRNA分析筛选上调的促凋亡基因,并构建荧光素酶报告细胞系进行验证。
主要发现
- rFSGS患者血浆可增加IL1β、BMF和IGFBP3报告细胞系的荧光素酶活性,而来自非复发FSGS或膜性肾病患者的血浆未引起报告活性增加。
- 区分rFSGS与其他肾病(非复发FSGS和膜性肾病)的AUC为0.81,区分rFSGS与非复发FSGS的AUC为0.86。
- IL1β和BMF细胞系诊断rFSGS的敏感性和特异性均大于80%,IGFBP3细胞系略低。
关键数值与推荐
- IL1β和BMF细胞系诊断rFSGS的敏感性和特异性均大于80%。
- 区分rFSGS与其他肾病及非复发FSGS的AUC分别为0.81和0.86。
临床怎么用
- 该检测有望作为非侵入性工具辅助诊断肾移植后rFSGS,减少对肾活检的依赖。
- 该技术平台可推广至其他肾小球疾病的诊断或预后检测开发。
局限性
- 研究为概念验证阶段,样本量未报告,需进一步扩大验证。
- IGFBP3细胞系的敏感性和特异性略低于IL1β和BMF细胞系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Definitive diagnosis of glomerular disease requires a kidney biopsy, an invasive procedure that may not be safe or feasible to perform in all patients. We developed a noninvasive, accurate, and economical diagnostic assay with easy commercial adaptability to detect recurrent focal segmental glomerulosclerosis (rFSGS) after kidney transplant. Since FSGS involves podocyte damage and death, our approach involved mRNA profiling of cultured podocytes treated with plasma from patients with rFSGS to identify upregulated genes involved in podocyte damage. For concept validation, three upregulated pro-apoptotic candidate genes (IL1β, BMF, and IGFBP3) were selected, and their promoter regions were cloned into a luciferase-based reporter vector and transfected into podocytes to generate stable podocyte cell lines. Strikingly, when exposed to rFSGS patient plasma, these cell lines showed increased reporter activity; in contrast, no reporter activity was noted with plasma from patients with non-recurrent FSGS or membranous nephropathy. Area under the receiver operating characteristics curves (AUCs) for models discriminating between rFSGS and other nephropathies (non-recurrent FSGS and membranous nephropathy) and between rFSGS and non-recurrent FSGS ranged from 0.81 to 0.86, respectively. Estimated sensitivities and specificities for the diagnosis of rFSGS were greater than 80% for the IL1β and BMF cell lines, and were slightly lower for the IGFBP3 cell line. Importantly, the novel approach outlined here for the diagnosis of rFSGS is widely applicable to the design of sensitive and specific diagnostic/prognostic assays for other glomerular diseases.
引用
- Srivastava P, Solanki AK, Arif E, et al. Development of a novel cell-based assay to diagnose recurrent focal segmental glomerulosclerosis patients. Kidney Int. 2019. PMID: 30709661. doi:10.1016/j.kint.2018.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。